Uncategorized Archives - Page 6 of 145

FridayAug 08, 2025 9:00 am

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF): The Cancer Detection Revolution That Could Make Breast Cancer Deaths Preventable

Izotropic’s IzoView Breast CT Imaging System represents a breakthrough in dedicated breast imaging technology, addressing persistent limitations in conventional screening methods through proprietary hardware and software FDA regulatory pathway alignment clears the path for a pivotal U.S. clinical study, with the company completing a comprehensive 150-page strategic business plan and advanced financial modeling for commercialization Strategic awareness initiatives including dedicated breastct.com platform and podcast series position the company for market education as breast CT technology emerges as the next generation of cancer detection The medical community stands at the threshold of what could become the most significant advancement in cancer…

ThursdayAug 07, 2025 10:30 am

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Advancing Next-Gen Breast Cancer Imaging

Breast cancer continues to be the most commonly diagnosed cancer among U.S. women, excluding nonmelanoma skin cancer Izotropic is preparing to revolutionize breast cancer imaging with its flagship IzoView Breast CT Imaging System In anticipation of future commercialization, Izotropic is initiating a strategic awareness and engagement campaign Accurate detection and diagnosis remain critical challenges in the fight against breast cancer, especially for women with dense breast tissue where mammography falls short. Izotropic (CSE: IZO) (OTCQB: IZOZF) is at the forefront of addressing these gaps through its IzoView Breast CT Imaging System, a contrast-enhanced CT platform designed for enhanced screening precision. The company…

ThursdayAug 07, 2025 9:00 am

Lantern Pharma Inc. (NASDAQ: LTRN) Completes Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial Ahead of Schedule

The trial targets never-smoker non-small cell lung cancer (“NSCLC”) patients, a group with limited treatment options. Japan’s high incidence of never-smoker NSCLC makes it a strategic region for the trial. LP-300 is being tested alongside standard chemotherapy agents in patients who have relapsed after tyrosine kinase inhibitor therapy. Lantern's AI-driven approach may help identify and accelerate development of therapies in underserved cancer markets. Additional trial data from Taiwan and the U.S. is expected later in Q3 2025. Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, has completed targeted patient…

WednesdayAug 06, 2025 12:10 pm

Lantern Pharma Inc. (NASDAQ: LTRN) Launches AI Tool to Predict Efficacy of Cancer Drug Combinations

Lantern Pharma has introduced an AI-powered module within its RADR(R) platform to assess DDA-DDRi combination therapies. The module uses genomic, transcriptomic, and clinical data, to predict treatment synergy and patient response, and supported the design of Lantern’s FDA-cleared Phase 1B/2 trial in triple-negative breast cancer. A review of 221 clinical trials informed the development of the predictive algorithm. Non-PARP DDRi combinations with DNA-damaging agents showed strong outcomes in specific cancer subtypes. Lantern is evaluating licensing opportunities to commercialize the module for broader oncology use. Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine…

WednesdayAug 06, 2025 11:30 am

HeartBeam Inc. (NASDAQ: BEAT) FDA-Cleared System Provides Momentum as Company Moves to Innovate Cardiac Care

The FDA-cleared HeartBeam system enables patients and physicians to access significant arrhythmia data outside traditional clinical settings. The HeartBeam system, credit card–sized and fully portable, represents a breakthrough in ambulatory cardiac care. Beyond ambulatory arrhythmia assessment, the platform is poised for future advancements, including synthesized 12-lead ECG generation. Foundational clearance from the U.S. Food and Drug Administration (“FDA”) for its patented HeartBeam system has proved pivotal for HeartBeam (NASDAQ: BEAT), a cardiac technology company focused on transforming the cardiac-care space (https://ibn.fm/0TAG4). The first cable-free, high-fidelity ECG device that captures the heart’s electrical activity from three distinct directions, the HeartBeam system…

WednesdayAug 06, 2025 10:50 am

Nutriband Inc. (NASDAQ: NTRB) Navigates Drug-Delivery Challenges with Innovation in Abuse-Deterrent Tech

Drug delivery plays a critical role in modern healthcare, but when it comes to potent opioids such as fentanyl, the stakes are particularly high Nutriband is developing Aversa(TM), a proprietary abuse-deterrent transdermal technology designed to prevent diversion, misuse, abuse and accidental exposure Nutriband’s Aversa(TM) fentanyl patch is estimated to have a market potential of $80 million to $200 million annually within five years of launch Developing safe, effective and abuse-deterrent delivery systems for controlled substances such as fentanyl is a formidable challenge, and Nutriband (NASDAQ: NTRB) is positioning itself at the forefront of that effort. The company is pioneering transdermal technologies to…

TuesdayAug 05, 2025 11:15 am

HeartBeam Inc.’s (NASDAQ: BEAT) Two New U.S. Patents Power Next Generation of Cardiac Diagnostics

Two newly issued patents mark a strategic advancement in HeartBeam’s proprietary technology. The first patent protects the company’s credit card–sized, cable-free 3D ECG device designed to capture high-fidelity electrical signals from three noncoplanar directions. The second patent covers the company’s rhythm analysis algorithm by continuously analyzing signal input. HeartBeam (NASDAQ: BEAT), a cardiac technology company, has secured two new U.S. patents that significantly enhance its intellectual property portfolio and strengthen its position in cardiac monitoring technology (https://ibn.fm/6xni4). The company, focused on delivering powerful, personalized insights into heart health through its innovative 3D ECG platform, now holds more than 20 U.S.…

TuesdayAug 05, 2025 9:00 am

Nutriband Inc. (NASDAQ: NTRB) Aligns Shareholder Value with FDA Milestone

FDA approval is a powerful inflection point in the lifecycle of any biopharmaceutical company Nutriband’s recent 25% preferred stock dividend uniquely ties shareholder reward to regulatory achievement CEO notes that “core goal is to continue to create value for our shareholders particularly as we near closer to the commercialization of AVERSA(TM) Fentanyl” Obtaining approval from the U.S. Food and Drug Administration (“FDA”) is a monumental achievement for any biopharmaceutical company, serving as a critical validation of a drug's safety and efficacy. This rigorous process is a cornerstone of public health, ensuring that only treatments proven to be beneficial and with acceptable…

TuesdayJul 29, 2025 1:45 pm

Why Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Is ‘One to Watch’

Izotropic is the only commercial entity with exclusive global rights to the Breast CT technology developed at UC Davis. The company has secured regulatory alignment with the FDA and is preparing for a pivotal U.S. clinical trial. IzoView offers a proprietary, patient-centric alternative to mammography for dense breast tissue imaging. A comprehensive business and financial plan supports execution across clinical, regulatory, and commercial milestones. Awareness campaigns, including breastct.com and a company podcast, are primed to drive engagement and investor visibility. Izotropic (CSE: IZO) (OTCQB: IZOZF) is a medical device company advancing dedicated imaging solutions to improve the screening, diagnosis, and treatment of…

MondayJul 28, 2025 9:00 am

Clene Inc. (NASDAQ: CLNN) Offers Investors a Compelling Entry into the Growing ALS Market with Key FDA Milestones for Lead Drug Candidate

Clene is progressing toward a potential FDA accelerated approval for its ALS (Amyotrophic Lateral Sclerosis) drug CNM-Au8® in 2026, a market that is expected to reach $1.3 billion by 2034 with significant unmet need. Clene’s technology targets mitochondrial dysfunction, a novel approach to neurodegenerative diseases, and key FDA meetings in the coming months of 2025 could be major valuation catalysts for investors. Biomarker and survival data from over 150 patients will be critical to the company’s regulatory case and expects important NfL data in the fourth quarter of 2025. Clene is preparing to initiate a confirmatory Phase 3 ALS trial…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF): The Cancer Detection Revolution That Could Make Breast Cancer Deaths Preventable

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Advancing Next-Gen Breast Cancer Imaging

Lantern Pharma Inc. (NASDAQ: LTRN) Completes Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial Ahead of Schedule

Lantern Pharma Inc. (NASDAQ: LTRN) Launches AI Tool to Predict Efficacy of Cancer Drug Combinations

HeartBeam Inc. (NASDAQ: BEAT) FDA-Cleared System Provides Momentum as Company Moves to Innovate Cardiac Care

Nutriband Inc. (NASDAQ: NTRB) Navigates Drug-Delivery Challenges with Innovation in Abuse-Deterrent Tech

HeartBeam Inc.’s (NASDAQ: BEAT) Two New U.S. Patents Power Next Generation of Cardiac Diagnostics

Nutriband Inc. (NASDAQ: NTRB) Aligns Shareholder Value with FDA Milestone

Why Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Is ‘One to Watch’

Clene Inc. (NASDAQ: CLNN) Offers Investors a Compelling Entry into the Growing ALS Market with Key FDA Milestones for Lead Drug Candidate

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search